Healthcare ETFs (exchange-traded funds) let investors gain diversified exposure to the health sector — from biopharmaceutical companies to medical equipment manufacturersHealthcare ETFs (exchange-traded funds) let investors gain diversified exposure to the health sector — from biopharmaceutical companies to medical equipment manufacturers

7 Best Healthcare ETFs for Long-Term Investors

2026/02/26 19:00
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Healthcare ETFs (exchange-traded funds) let investors gain diversified exposure to the health sector — from biopharmaceutical companies to medical equipment manufacturers — through a single product. Because healthcare demand tends to grow over time (thanks to ageing populations, ongoing innovation and consistent spending), these ETFs can be excellent long-term holdings in a diversified investment portfolio.

This article explores 7 top healthcare ETFs so you can decide which best fits your investment style:

7 Best Healthcare ETFs for Long-Term Investors

1. Health Care Select Sector SPDR Fund (XLV)

Overview: The XLV ETF tracks the Health Care Select Sector Index, which is a broad basket of US healthcare companies spanning pharmaceuticals, biotechnology, medical equipment and managed care. It’s one of the most popular healthcare ETFs by assets and liquidity.

Why Long-Term Investors Like It:

  • Offers broad exposure to major healthcare players

  • Focuses on established, lower-volatility companies

Pros and Cons

Very liquid and widely heldBroad exposure across healthcare subsectorsStrong historical performance as a defensive playHeavily weighted toward large caps (less small-cap upside)Sector-specific risks still apply

2. Vanguard Health Care ETF (VHT)

Overview: VHT tracks the performance of a broad US healthcare index that includes large, mid and small caps. It’s known for low costs and diversified sector exposure.

Why It’s Great for Long-Term Investing: VHT spreads investments across hundreds of healthcare companies from established blue chips to emerging players.

Pros and Cons

Extremely diversified healthcare exposureLow expense ratioGood mix of growth and stabilityStill concentrated in US healthcareCosts, while low, are higher than XLV

3. iShares Biotechnology ETF (IBB)

Overview: IBB tracks the Nasdaq Biotechnology Index, giving investors access to biotech and pharmaceutical companies listed on the Nasdaq exchange.

Why It’s Attractive: This ETF is suited to growth-oriented investors who want targeted exposure to drug development and biotech innovation.

Pros and Cons

Strong exposure to biotech growthIncludes many innovative, high-potential companiesGood liquidityHigher volatility than broad healthcare ETFsSensitive to biotech swings and regulatory news

4. SPDR S&P Biotech ETF (XBI)

Overview: Unlike IBB, XBI is equal-weighted. This means that each holding is roughly the same size rather than weighted by market cap. This can increase exposure to smaller biotech firms.

Why Investors Choose It: Equal weighting helps avoid overconcentration in a few large companies and gives more balanced biotech coverage.

Pros and Cons

Equal-weight structure reduces mega-cap dominanceBroader representation of biotech firmsPotentially higher growth when smaller names outperformVery volatile compared to sector-wide fundsMore sensitive to biotech sector downturns

5. iShares U.S. Healthcare ETF (IYH)

Overview: IYH tracks a broad index of US healthcare equities, including medical equipment makers, drug companies and health services.

Why It’s Worth Considering: It provides a wide lens on the US healthcare landscape without focusing on a single niche.

Pros and Cons

Broad US healthcare exposureGood balance of defensive and growth stocksLower turnoverSimilar to XLV — may overlap with other broad fundsLimited international exposure

6. iShares Global Healthcare ETF (IXJ)

Overview: IXJ expands the lens beyond the US by tracking global healthcare companies in developed markets.

Why Global Exposure Matters: For long-term investors, diversifying healthcare holdings beyond the US offers potential growth and risk mitigation.

Pros and Cons

Diversified across global healthcare leadersHelps hedge against regional market downturnsInternational currency riskCan have higher tracking error vs US funds

7. Fidelity MSCI Health Care Index ETF (FHLC)

Overview: FHLC tracks the MSCI US Health Care Inde. This is a broad measure of US healthcare stocks including pharmaceuticals and services.

Why It’s a Solid All-Around Choice: It offers a low-cost way to invest in a wide range of healthcare companies.

Pros and Cons

Low costWide sector coveragePassive, transparent approachSimilar to Vanguard and iShares broad fundsMay lag in strong biotech rallies

How to Choose the Right Healthcare ETF

When deciding which healthcare ETF fits your long-term goals, consider:

  • Risk tolerance: Biotech-focused funds like IBB and XBI are higher risk but offer more growth potential.

  • Diversification: Broad funds like XLV and VHT spread your exposure across multiple subsectors.

  • Geographic focus: IXJ brings global perspective, while others focus mainly on U.S. stocks.

Final Thoughts

Healthcare ETFs can be valuable core or satellite holdings for a long-term investing strategy. They provide diversified access to a sector supported by structural trends like ageing populations, consistent demand for medical services, and technological innovation. By weighing each ETF’s strategy, holdings and risk profile, you can build a healthcare slice of your portfolio aligned with your goals. 

Market Opportunity
Prosper Logo
Prosper Price(PROSPER)
$0.02095
$0.02095$0.02095
+0.19%
USD
Prosper (PROSPER) Live Price Chart

World Cup Combo: Aim for 200x

World Cup Combo: Aim for 200xWorld Cup Combo: Aim for 200x

Combine up to 20 World Cup matches in one order

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

CME Group to launch Solana and XRP futures options in October

CME Group to launch Solana and XRP futures options in October

The post CME Group to launch Solana and XRP futures options in October appeared on BitcoinEthereumNews.com. CME Group is preparing to launch options on SOL and XRP futures next month, giving traders new ways to manage exposure to the two assets.  The contracts are set to go live on October 13, pending regulatory approval, and will come in both standard and micro sizes with expiries offered daily, monthly and quarterly. The new listings mark a major step for CME, which first brought bitcoin futures to market in 2017 and added ether contracts in 2021. Solana and XRP futures have quickly gained traction since their debut earlier this year. CME says more than 540,000 Solana contracts (worth about $22.3 billion), and 370,000 XRP contracts (worth $16.2 billion), have already been traded. Both products hit record trading activity and open interest in August. Market makers including Cumberland and FalconX plan to support the new contracts, arguing that institutional investors want hedging tools beyond bitcoin and ether. CME’s move also highlights the growing demand for regulated ways to access a broader set of digital assets. The launch, which still needs the green light from regulators, follows the end of XRP’s years-long legal fight with the US Securities and Exchange Commission. A federal court ruling in 2023 found that institutional sales of XRP violated securities laws, but programmatic exchange sales did not. The case officially closed in August 2025 after Ripple agreed to pay a $125 million fine, removing one of the biggest uncertainties hanging over the token. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication. Get the news in your inbox. Explore Blockworks newsletters: Source: https://blockworks.co/news/cme-group-solana-xrp-futures
Share
BitcoinEthereumNews2025/09/17 23:55
GOP in disarray as Senate seat pick-up slips away: 'It's a mess'

GOP in disarray as Senate seat pick-up slips away: 'It's a mess'

The Republican Party's dysfunction in Georgia is turning what should have been a winnable Senate seat into a likely Democratic victory. The culprit: Donald Trump
Share
Rawstory2026/04/02 19:22
Solana Price Prediction: SOL Slides Below $80 As $270M Hack Triggers Selloff

Solana Price Prediction: SOL Slides Below $80 As $270M Hack Triggers Selloff

The post Solana Price Prediction: SOL Slides Below $80 As $270M Hack Triggers Selloff appeared first on Coinpedia Fintech News Solana price is back under pressure
Share
CoinPedia2026/04/02 18:59